News tagged with glivec
Related topics: cancer drugs
Imatinib
Imatinib (originally STI571) is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia/Latin America) as its mesylate salt, imatinib mesilate (INN). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and some other diseases. By 2011, Gleevec has been FDA approved to treat ten different cancers. In CML, the tyrosine kinase enzyme ABL is locked in its activated form. It induces the abnormal phenotypes of CML: excessive proliferation and high white blood cell count. Imatinib binds to the site of tyrosine kinase activity, and prevents its activity, thereby causing tumor cell apoptosis.
Imatinib is the first member of a new class of agents that act by specifically inhibiting a certain enzyme that is characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells, and served as a model for other targeted therapy modalities through tyrosine kinase inhibition.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Doctors say cancer drug costs are too high
More than 100 doctors from around the world have signed a letter decrying the high cost of cancer drugs which reach $100,000 per year or more, and calling for pharmaceutical companies to ease prices.
Medications
Apr 26, 2013 |
5 / 5 (4) |
2
Drug maker Novartis loses India patent battle (Update)
India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world ...
Medications
Apr 01, 2013 |
5 / 5 (3) |
0
India's top court to deliver Novartis judgment
India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies ...
Medications
Mar 31, 2013 |
not rated yet |
0
Multi-tasking imatinib boosts radiotherapy for bladder tumours
Cancer drug imatinib (Glivec) could boost radiotherapy treatment to destroy bladder cancer that has spread to the bladder wall, reveals research published in Cancer Research.
Cancer
Mar 04, 2013 |
not rated yet |
0
Indian court to rule on generic drug industry
(AP)—From Africa's crowded AIDS clinics to the malarial jungles of Southeast Asia, the lives of millions of ill people in the developing world are hanging in the balance ahead of a legal ruling that will ...
Medications
Jan 04, 2013 |
not rated yet |
0
Improved treatments for chronic myeloid leukaemia have dramatically increased survival
Survival for people diagnosed with Chronic Myeloid Leukaemia (CML) has risen by nearly half, with around 58 per cent of people surviving their disease for at least five years compared with only around 40 p ...
Cancer
Dec 12, 2012 |
not rated yet |
0
Cancer drugs could halt Ebola virus
Some cancer drugs used to treat patients with leukemia may also help stop the Ebola virus and give the body time to control the infection before it turns deadly, US researchers said on Wednesday.
Medications
Feb 29, 2012 |
5 / 5 (1) |
0
Novartis fights patent rejection in Indian court
(AP) -- In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis ...
Medications
Sep 06, 2011 |
5 / 5 (3) |
0
India patent case threatens cheap drug supply: MSF
Supply of cheap, copycat drugs for the developing world could be badly threatened if Swiss firm Novartis wins a challenge to India's patent law, medical charity MSF said on Monday.
Medications
Sep 05, 2011 |
5 / 5 (4) |
1
